Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| RECT | Rectitude | $2.27 | $1.07 | 89.17% | 4.7M | $17M | $1.00$5.21 |
| BTM | Bitcoin Depot | $4.02 | $1.39 | 52.85% | 85.6K | $29M | $1.91$48.16 |
| MNTS | Momentus | $4.93 | $1.45 | 41.67% | 8.3M | $20M | $3.11$43.55 |
| ALMU | Aeluma | $15.23 | $4.47 | 41.54% | 12M | $194M | $6.08$25.88 |
| RVMD | Revolution Medicines | $136.18 | $39.75 | 41.22% | 11.7M | $19B | $34.00$136.42 |
| XNDU | Xanadu Quantum Technologies | $12.08 | $3.12 | 34.82% | 1.8M | $203M | $6.97$12.97 |
| LICN | Lichen International | $4.17 | $0.98 | 30.72% | 131.7K | $52M | $2.57$8.28 |
| HURA | TuHURA Biosciences | $2.93 | $0.66 | 28.86% | 3.3M | $144M | $0.41$4.44 |
| HHS | Harte Hanks | $3.03 | $0.67 | 28.16% | 82.9K | $18M | $2.22$5.39 |
| BCG | Binah Capital Group | $2.23 | $0.47 | 26.76% | 739.2K | $29M | $1.36$3.44 |
| SYRE | Spyre Therapeutics | $65.00 | $13.71 | 26.72% | 4.4M | $4.0B | $12.04$75.00 |
| BNAI | Brand Engagement Network | $52.12 | $10.06 | 23.92% | 813.8K | $245M | $1.18$86.28 |
| ORCU | Direxion Shares ETF Trust - Daily Orcl Bull 2x Etf | $10.36 | $1.96 | 23.27% | 1.7M | - | $7.99$27.62 |
| ORCX | Tidal Trust II - Defiance Daily Target 2x Long Orcl ETF | $29.02 | $5.45 | 23.10% | 4.5M | - | $22.37$181.59 |
| MTC | MMTec | $7.02 | $1.30 | 22.73% | 96.9K | $570M | $0.25$7.27 |
| IMA | ImageneBio | $5.97 | $1.07 | 21.79% | 17.8M | $55M | $3.94$18.00 |
| LNZA | LanzaTech Global | $33.00 | $5.85 | 21.55% | 32.5K | $274M | $7.88$71.19 |
| MOVE | Corvex | $13.20 | $2.30 | 21.10% | 74.5K | $18M | $3.44$25.68 |
| OPTX | Syntec Optics | $11.23 | $1.88 | 20.11% | 136.2K | $346M | $1.04$12.20 |
| TBRG | TruBridge | $21.55 | $3.57 | 19.86% | 1.1M | $268M | $13.88$26.74 |
| CDT | Cdt Equity | $4.89 | $0.81 | 19.73% | 63.5K | $19M | $3.64$3,030.00 |
| CLLS | Cellectis | $4.29 | $0.70 | 19.50% | 294K | $260M | $1.33$5.48 |
| CRCG | Themes ETF Trust - Leverage Shares 2x Long Crcl Daily ETF | $2.71 | $0.44 | 19.38% | 25.5M | - | $0.95$20.92 |
| RMIX | Suncrete | $13.30 | $2.15 | 19.32% | 166.3K | $325M | $9.20$13.51 |
| CSHR | CoinShares International | $6.14 | $0.99 | 19.22% | 418.4K | $681M | $4.72$13.70 |
| HIMZ | Tidal Trust II - Defiance Daily Target 2x Long Hims ETF | $23.60 | $3.79 | 19.13% | 1.4M | - | $12.38$780.77 |
| NETG | Themes ETF Trust - Leverage Shares 2x Long Net Daily ETF | $9.08 | $1.43 | 18.69% | 396.4K | - | $7.40$15.17 |
| LACG | Themes ETF Trust - Leverage Shares 2x Long Lac Daily ETF | $8.89 | $1.37 | 18.19% | 11.5K | - | $6.34$26.22 |
| PHOE | Phoenix Asia | $16.00 | $1.60 | 11.11% | 5.6K | $311M | $2.31$133.12 |
| VACHU | Voyager Acquisition Corp. | $10.40 | -$1.10 | -9.56% | 1 | $329M | $10.08$14.41 |
Related Articles
Featured Article
3 Growth Stocks That Could 10X Over the Next 10 Years
Daniel Foelber, Scott Levine, and Lee Samaha|Apr 30, 2023
These companies are investing in paradigm-shifting trends.
This 2020 Biotech IPO Is Poised to Break Out in 2021
Patrick Bafuma|Apr 2, 2021
Revolution Medicines' leading compound is shaping up to be a platform in a pill.
Investors Scrambled to Buy This Biotech IPO
Jim Crumly|Feb 21, 2020
Shares of cancer-specialist Revolution Medicines soared on its first day of public trading.
These Gene-Editing Pioneers Are Making Bold Bets in Agriculture
Maxx Chatsko|Jan 18, 2020
Investors shouldn't forget that the world of biotech extends beyond biopharmaceuticals.
Did Cellectis Just Provide a Glimpse of the Future of Cellular Medicine?
Maxx Chatsko|Dec 23, 2019
The gene editing company published a proof-of-concept for "smart" immunotherapies. The idea may catch on.
3 IPOs That Have More Than Tripled in 2019
Rick Munarriz|Jul 1, 2019
Beyond Meat, MMTec, and ShockWave Medical are the three hottest IPOs through the first half of this year.
George Soros Bought This Under-the-Radar Biotech Stock: Should You?
George Budwell, PhD|Aug 20, 2018
Soros Fund Management picked up a healthy stake in rare-disease and cancer drugmaker Aeglea BioTherapeutics in the second quarter.
Is Cellectis SA Stock a Buy Now?
Cory Renauer|Apr 7, 2018
Despite getting passed along to a biotech start-up, Cellectis could have a bright future.
Can Been-There Biotech Entrepreneur Arie Belldegrun Do It Yet Again?
Todd Campbell|Apr 6, 2018
Belldegrun's Allogene Therapeutics has just inked a transformative deal to land Pfizer's CAR-T cancer gene therapy program.
Why Micron Technology, Mechel, and Cellectis Slumped Today
Dan Caplinger|Apr 5, 2018
Find out why these stocks missed out on the rally.
